★
Trade Filings
Managers Aandelen Ingediende stukken Superinvesteerders
Signalen Institutionele aankopen Institutionele verkopen Insider-activiteit 13D & 13G Watch Sectorrotatie
Tools Aandelenscreener Manager Screener Beheerders vergelijken Consensusmandjes Alle onderzoekstools Data-API
Leren & AI Leren Vraag de data AI-agents
Nieuws ★ Opgeslagen
Over Over ons Methodologie Contact Disclaimer
Reader
DATAPAKKETTEN

Downloads van historische gegevens — beschikbaar met accounts.

API GATEWAY

Gratis alleen-lezen JSON-toegang tot de gecachede gegevens van de site.
Donkere modus

🧭 Begeleide weergave
Nieuw met markten — koersen, yields, YTD, marktkapitalisatie? We leggen elk begrip uit terwijl u bladert, in begrijpelijke taal. Dezelfde data, met ingebouwde uitleg.

⚡ Expertvisie
U kent de markt al. Alleen de data — schoon, snel en compact, zonder extra uitleg. Dit is de standaardweergave.

Interfacetaal
Effectdossier · gearchiveerd kwartaal

LLY

Eli Lilly and Company · Healthcare · Drug Manufacturers - General

1,233.5 -1.1% marktkapitalisatie $1.16T koers vertraagd (FMP) · per Aug 25 22:08 UTC — los van onderstaande aangiftegegevens

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024
27Gevolgde houders
-3Δ houders
329.88MGehouden aandelen
$251.63BGerapporteerde waarde
+2Nieuwe posities
−6Uitstappen
Falling Overtuigingsscore 36/100 2 kwartalen van stijgende gevolgde aandelen ●●○○○○ Hoe deze worden berekend → Dit toelichten aan de Research Desk →

Momentum-inputs (vergelijkbare managers): breedte van houders -10.0% · aandelenstroom -2.5% · netto nieuwe posities -14.8% — formule
Brede distributie — dalende aandelen en minder houders

Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025

Eigendom in de tijd
KwartaalHoudersΔAandelenGerapporteerde waardeNieuwUitstappen
Q2 2026 193 +4 671.92M $804.91B +6 −1
Q1 2026 191 -3 666.59M $613.20B +1 −5
Q4 2025 193 +2 707.04M $758.81B +3 —
Q3 2025 27 -3 329.88M $251.63B +2 −6
Q2 2025 28 -1 307.45M $239.60B +2 −3
Q1 2025 26 0 140.32M $115.83B +1 −1
Q4 2024 26 +1 145.00M $111.91B +3 −2
Q3 2024 24 +2 109.89M $97.29B +2 —
Q2 2024 22 — 112.43M $101.75B — —
Aantal houders
Wie het bezit · Q3 2025
#ManagerAandelenΔ aandelenWaardeHun gewichtGehouden
1 The Vanguard Group ✦ (passief) 80.96M +0.7% $61.77B 0.9% ▲ Add 2 SEC ↗
2 The Vanguard Group ✦ (passief) 80.96M +0.7% $61.77B 0.9% ▲ Add 2 SEC ↗
3 The Vanguard Group ✦ (passief) 80.96M +0.7% $61.77B 0.9% ▲ Add 2 SEC ↗
4 The Vanguard Group ✦ (passief) 80.96M +0.7% $61.77B 0.9% ▲ Add 2 SEC ↗
5 The Vanguard Group ✦ (passief) 80.96M +0.7% $61.77B 0.9% ▲ Add 2 SEC ↗
6 The Vanguard Group ✦ (passief) 80.96M +0.7% $61.77B 0.9% ▲ Add 2 SEC ↗
7 The Vanguard Group ✦ (passief) 80.96M +0.7% $61.77B 0.9% ▲ Add 2 SEC ↗
8 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
9 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
10 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
11 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
12 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
13 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
14 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
15 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
16 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
17 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
18 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
19 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
20 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
21 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
22 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
23 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
24 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
25 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
26 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
27 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
28 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
29 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
30 BlackRock ✦ (passief) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
31 State Street Global Advisors ✦ (passief) 34.73M +0.6% $26.50B 0.9% ▲ Add 4 SEC ↗
32 Fidelity (FMR) ✦ 24.17M -5.7% $18.44B 1.0% ▼ Trim 2 SEC ↗
33 Fidelity (FMR) ✦ 24.17M -5.7% $18.44B 1.0% ▼ Trim 2 SEC ↗
34 Fidelity (FMR) ✦ 24.17M -5.7% $18.44B 1.0% ▼ Trim 2 SEC ↗
35 Fidelity (FMR) ✦ 24.17M -5.7% $18.44B 1.0% ▼ Trim 2 SEC ↗
36 Fidelity (FMR) ✦ 24.17M -5.7% $18.44B 1.0% ▼ Trim 2 SEC ↗
37 Fidelity (FMR) ✦ 24.17M -5.7% $18.44B 1.0% ▼ Trim 2 SEC ↗
38 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
39 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
40 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
41 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
42 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
43 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
44 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
45 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
46 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
47 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
48 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
49 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
50 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
51 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
52 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
53 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
54 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
55 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
56 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
57 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
58 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
59 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
60 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
61 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
62 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
63 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
64 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
65 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
66 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
67 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
68 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
69 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
70 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
71 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
72 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
73 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
74 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
75 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
76 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
77 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
78 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
79 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
80 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
81 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
82 Geode Capital Management ✦ (passief) 19.82M +9.3% $15.07B 1.0% ▲ Add 6 SEC ↗
83 Geode Capital Management ✦ (passief) 19.82M +9.3% $15.07B 1.0% ▲ Add 6 SEC ↗
84 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
85 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
86 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
87 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
88 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
89 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
90 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
91 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
92 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
93 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
94 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
95 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
96 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
97 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
98 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
99 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
100 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗

"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.

Nieuwe kopers

Geen nieuwe bijgehouden kopers dit kwartaal.

Verlaten

Norges Bank $8.83B was 1.1%
Tiger Global Management $1.18B was 3.5%
Viking Global Investors $325.00M was 0.9%
Coatue Management $91.53M was 0.3%
Duquesne Family Office $78.48M was 2.0%
Renaissance Technologies $204,662 was 0.0%

Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 4,323 houders, 762.84M aandelen, $674.93B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.

Vaak gezamenlijk in bezit

Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.

MCD27gedeelde houders NVDA27gedeelde houders MSFT27gedeelde houders CVS27gedeelde houders KO27gedeelde houders
Insider-transacties

Open-market aankopen (P)

Geen open-market insider-aankopen in ons dekkingsvenster.

Open-market verkopen (S)

Aug 17 Jonsson Patrik

Officer · 6.50K aand · $7.64M

Aug 10 Zakrowski Donald A

Officer · 2.00K aand · $2.37M

Aug 07 Hakim Anat

Officer · 5.00K aand · $5.95M

Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie

Beneficial ownership
Jul 23 SC 13G/A — LILLY ENDOWMENT INC

Originele SEC-indiening bekijken ↗
In het nieuws
Aug 24 FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test ↗

The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…

 Forbes
Aug 24 FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly ↗

The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…

 WSJ
Aug 24 Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance ↗

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help ​identify signs of…

 Reuters
Aug 24 Eli Lilly Launches Foundayo Weight-Loss Pill in U.K. ↗

The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…

 WSJ
Aug 23 Eli Lilly launches oral weight-loss pill Foundayo in UK ↗

Eli Lilly said on Monday it has launched its oral pill, ​Foundayo, in the UK for weight ‌management and type 2…

 Reuters
Herkomst: Eigendom op basis van geparseerde 13F common-stockposities (gevolgde universum, vergelijkbare sets voor wijzigingen); insider-rijen afkomstig van formulieren 3/4/5; belangen uit Schedules 13D/13G; elke indiening verwijst naar het origineel op SEC EDGAR. Rapportageperiode: Q3 2025 · Methodologie · Verkrijg dit via de API